Form: TH-04



townhall.virginia.gov

# Fast-Track Regulation Agency Background Document

Agency name	Board of Pharmacy, Department of Health Professions	
Virginia Administrative Code (VAC) citation(s)		
Regulation title(s)	Regulations Governing the Practice of Pharmacy	
Action title Partial fill of prescriptions		
Date this document prepared	3/28/17	

This information is required for executive branch review and the Virginia Registrar of Regulations, pursuant to the Virginia Administrative Process Act (APA), Executive Orders 17 (2014) and 58 (1999), and the *Virginia Register Form, Style, and Procedure Manual.* 

## **Brief summary**

Please provide a brief summary (preferably no more than 2 or 3 paragraphs) of the proposed new regulation, proposed amendments to the existing regulation, or the regulation proposed to be repealed. Alert the reader to all substantive matters or changes. If applicable, generally describe the existing regulation.

Regulations for partial dispensing of a Schedule II controlled substance are amended to allow a partial fill if requested by the patient or the prescriber and if: 1) the total quantity of all partial fillings doesn't exceed the total prescribed; 2) the prescription is written and filled in accordance with state and federal law; and 3) the remaining portions are filled not later than 30 days from the original date on the prescription.

# **Acronyms and Definitions**

Please define all acronyms used in the Agency Background Document. Also, please define any technical terms that are used in the document that are not also defined in the "Definition" section of the regulations.

Form: TH-04

DEA = U. S. Drug Enforcement Administration

### Statement of final agency action

Please provide a statement of the final action taken by the agency including:1) the date the action was taken; 2) the name of the agency taking the action; and 3) the title of the regulation.

On March 21, 2017, the Board of Pharmacy adopted amendments to 18VAC110-20-10 et seq., Regulations Governing the Practice of Pharmacy.

# **Legal basis**

Please identify the state and/or federal legal authority to promulgate this proposed regulation, including: 1) the most relevant citations to the Code of Virginia or General Assembly chapter number(s), if applicable; and 2) promulgating entity, i.e., agency, board, or person. Your citation should include a specific provision authorizing the promulgating entity to regulate this specific subject or program, as well as a reference to the agency/board/person's overall regulatory authority.

Regulations are promulgated under the general authority of Chapter 24 of Title 54.1 of the Code of Virginia. Section 54.1-2400, which provides the Board of Pharmacy the authority to promulgate regulations to administer the regulatory system and a specific mandate of Chapter 82 of the 2016 General Assembly:

#### § 54.1-2400. General powers and duties of health regulatory boards.

*The general powers and duties of health regulatory boards shall be:* 

...6. To promulgate regulations in accordance with the Administrative Process Act (§  $\underline{2.2-4000}$  et seq.) that are reasonable and necessary to administer effectively the regulatory system, which shall include provisions for the satisfaction of board-required continuing education for individuals registered, certified, licensed, or issued a multistate licensure privilege by a health regulatory board through delivery of health care services, without compensation, to low-income individuals receiving health services through a local health department or a free clinic organized in whole or primarily for the delivery of those health services. Such regulations shall not conflict with the purposes and intent of this chapter or of Chapter 1 (§  $\underline{54.1-100}$  et seq.) and Chapter 25 (§  $\underline{54.1-2500}$  et seq.).

The statutory authority for the Board to promulgate regulations to regulate the security and integrity of drugs and devices is found in:

#### § 54.1-3307. Specific powers and duties of Board.

A. The Board shall regulate the practice of pharmacy and the manufacturing, dispensing, selling, distributing, processing, compounding, or disposal of drugs and devices. The Board shall also control the character and standard of all drugs, cosmetics and devices within the Commonwealth, investigate all complaints as to the quality and strength of all drugs, cosmetics, and devices and take such action as may be necessary to prevent the manufacturing, dispensing, selling, distributing, processing, compounding and disposal of such drugs, cosmetics and devices that do not conform to the requirements of law.

Form: TH-04

The Board's regulations shall include criteria for:

- 1. Maintenance of the quality, quantity, integrity, safety and efficacy of drugs or devices distributed, dispensed or administered.
- 2. Compliance with the prescriber's instructions regarding the drug, its quantity, quality and directions for use.
- 3. Controls and safeguards against diversion of drugs or devices.
- 4. Maintenance of the integrity of, and public confidence in, the profession and improving the delivery of quality pharmaceutical services to the citizens of Virginia.
- 5. Maintenance of complete records of the nature, quantity or quality of drugs or substances distributed or dispensed, and of all transactions involving controlled substances or drugs or devices so as to provide adequate information to the patient, the practitioner or the Board.
- 6. Control of factors contributing to abuse of legitimately obtained drugs, devices, or controlled substances.
- 7. Promotion of scientific or technical advances in the practice of pharmacy and the manufacture and distribution of controlled drugs, devices or substances.
- 8. Impact on costs to the public and within the health care industry through the modification of mandatory practices and procedures not essential to meeting the criteria set out in subdivisions 1 through 7 of this section.
- 9. Such other factors as may be relevant to, and consistent with, the public health and safety and the cost of rendering pharmacy services.

#### **Purpose**

Please explain the need for the new or amended regulation. Describe the rationale or justification of the proposed regulatory action. Describe the specific reasons the regulation is essential to protect the health, safety or welfare of citizens. Discuss the goals of the proposal and the problems the proposal is intended to solve.

The purpose of the amended regulation is to offer more flexibility in dispensing Schedule II drugs, so the drug is not dispensed in a quantity beyond what the patient or prescriber initially desires. The prescriber may write for a seven-day or 14-day (for post-surgical) supply, but the patient may prefer to try the drug for a few days before filling the full prescription. For example, a patient may be prescribed an opioid for pain after a procedure in the doctor's office. To avoid having a quantity of drugs which may or may not be needed, he may request a partial fill with the ability to have the remainder dispensed if necessary. The partial fill may have a cost-savings advantage, especially for self-pay patients, but the primary advantage would be the potential of having fewer unused or unnecessary Schedule II drugs available for abuse or diversion. The goal is to meet a patient's need for medication but offer greater protection for public health and safety.

Form: TH-04

## Rationale for using fast-track process

Please explain the rationale for using the fast-track process in promulgating this regulation. Why do you expect this rulemaking to be noncontroversial?

The ability for a pharmacist to partially fill a Schedule II prescription at the request of a patient or a prescriber is consumer-friendly, less restrictive, and not controversial. Therefore, a fast-track process is appropriate.

#### **Substance**

Please briefly identify and explain the new substantive provisions, the substantive changes to existing sections, or both. A more detailed discussion is provided in the "Detail of changes" section below.

Regulations for partial dispensing of a Schedule II controlled substance are amended to allow a partial fill if requested by the patient or the prescriber and if: 1) the total quantity of all partial fillings doesn't exceed the total prescribed; 2) the prescription is written and filled in accordance with state and federal law; and 3) the remaining portions are filled not later than 30 days from the original date on the prescription.

#### **Issues**

Please identify the issues associated with the proposed regulatory action, including: 1) the primary advantages and disadvantages to the public, such as individual private citizens or businesses, of implementing the new or amended provisions; 2) the primary advantages and disadvantages to the agency or the Commonwealth; and 3) other pertinent matters of interest to the regulated community, government officials, and the public. If there are no disadvantages to the public or the Commonwealth, please indicate.

- 1) The advantage to the public is an option for partial filling of a Schedule II prescription as requested. There are no disadvantages.
- 2) There are no advantages or disadvantages to this agency or the Commonwealth.

3) The Director of the Department of Health Professions has reviewed the proposal and performed a competitive impact analysis. The Board is authorized under § 54.1-2400 to promulgate regulations in accordance with the Administrative Process Act (§ 2.2-4000 et seq.) that are reasonable and necessary to administer effectively the regulatory system. Such regulations shall not conflict with the purposes and intent of this chapter or of Chapter 1 (§ 54.1-100 et seq.) and Chapter 25 (§ 54.1-2500 et seq.) This proposal is permissive and less restrictive, so there is no restraint on competition as a result of this action.

Form: TH-04

## **Requirements more restrictive than federal**

Please identify and describe any requirement of the proposal which is more restrictive than applicable federal requirements. Include a rationale for the need for the more restrictive requirements. If there are no applicable federal requirements or no requirements that exceed applicable federal requirements, include a statement to that effect.

The proposed regulations are consistent applicable federal requirements of the DEA.

## **Localities particularly affected**

Please identify any locality particularly affected by the proposed regulation. Locality particularly affected means any locality which bears any identified disproportionate material impact which would not be experienced by other localities.

There are no localities particularly affected.

# Regulatory flexibility analysis

Pursuant to § 2.2-4007.1B of the Code of Virginia, please describe the agency's analysis of alternative regulatory methods, consistent with health, safety, environmental, and economic welfare, that will accomplish the objectives of applicable law while minimizing the adverse impact on small business. Alternative regulatory methods include, at a minimum: 1) the establishment of less stringent compliance or reporting requirements; 2) the establishment of less stringent schedules or deadlines for compliance or reporting requirements; 3) the consolidation or simplification of compliance or reporting requirements; 4) the establishment of performance standards for small businesses to replace design or operational standards required in the proposed regulation; and 5) the exemption of small businesses from all or any part of the requirements contained in the proposed regulation.

There is no alternative to the adoption of amendments to regulations to accomplish the intent of this action.

# **Economic impact**

Please identify the anticipated economic impact of the proposed new regulations or amendments to the existing regulation. When describing a particular economic impact, please specify which new requirement or change in requirement creates the anticipated economic impact.

Droiseted coet to the etete to implement and	A
Projected cost to the state to implement and	As a special fund agency, the Board must generate
enforce the proposed regulation, including:	sufficient revenue to cover its expenditures from
a) fund source / fund detail; and	non-general funds, specifically the renewal and
b) a delineation of one-time versus on-going	application fees it charges to practitioners or entities
expenditures	for necessary functions of regulation. All
	notifications will be done electronically.
	There are no on-going expenditures.
Projected cost of the new regulations or	None
changes to existing regulations on localities.	
Description of the individuals, businesses, or	Permitted pharmacies
other entities likely to be affected by the new	1
regulations or changes to existing regulations.	
Agency's best estimate of the number of such	There are 1852 permitted pharmacies. There is no
entities that will be affected. Please include an	estimate of the number that might be affected; not
estimate of the number of small businesses	all pharmacies dispense drugs to the general public.
<b>affected.</b> Small business means a business entity,	Pharmacies are permitted generally and not
including its affiliates, that:	identified by the services they provide or by their
a) is independently owned and operated and;	cliental.
b) employs fewer than 500 full-time employees or	Circitati.
has gross annual sales of less than \$6 million.	
All projected costs of the new regulations or	There would be no additional cost.
changes to existing regulations for affected	
individuals, businesses, or other	
entities. Please be specific and include all	
costs including: a) the projected reporting, recordkeeping, and	
other administrative costs required for	
compliance by small businesses; and	
b) specify any costs related to the development	
of real estate for commercial or residential	
purposes that are a consequence of the	
proposed regulatory changes or new	
regulations.	
Beneficial impact the regulation is designed	The beneficial impact will be more flexibility for
to produce.	patients and prescribers to try a prescribed
	medication without having the full prescription
	filled at the outset.
	inioa at the outpet.

Form: TH-04

#### **Alternatives**

Please describe any viable alternatives to the proposal considered and the rationale used by the agency to select the least burdensome or intrusive alternative that meets the essential purpose of the action. Also, include discussion of less intrusive or less costly alternatives for small businesses, as defined in § 2.2-4007.1 of the Code of Virginia, of achieving the purpose of the regulation.

There are no viable alternatives that will achieve the purpose of the regulation. The Regulation Committee recommended an amendment to the Board's regulations on partial filling of Schedule II prescriptions, provided the changes would be consistent with the Comprehensive Addiction and Recovery Act (CARA) of 2016. The Board reviewed Section 309 of the Controlled

Substances Act (21 U.S.C. 829) and concluded that the language proposed is in compliance with CARA

Form: TH-04

## **Public participation notice**

If an objection to the use of the fast-track process is received within the 30-day public comment period from 10 or more persons, any member of the applicable standing committee of either house of the General Assembly or of the Joint Commission on Administrative Rules, the agency shall: 1) file notice of the objections with the Registrar of Regulations for publication in the Virginia Register; and 2) proceed with the normal promulgation process with the initial publication of the fast-track regulation serving as the Notice of Intended Regulatory Action.

## **Family impact**

Please assess the impact of this regulatory action on the institution of the family and family stability including to what extent the regulatory action will: 1) strengthen or erode the authority and rights of parents in the education, nurturing, and supervision of their children; 2) encourage or discourage economic self-sufficiency, self-pride, and the assumption of responsibility for oneself, one's spouse, and one's children and/or elderly parents; 3) strengthen or erode the marital commitment; and 4) increase or decrease disposable family income.

There is no impact on the institution of the family and family stability.

## **Detail of changes**

Please list all changes that are being proposed and the consequences of the proposed changes; explain the new requirements and what they mean rather than merely quoting the proposed text of the regulation. If the proposed regulation is a new chapter, describe the intent of the language and the expected impact. Please describe the difference between existing regulation(s) and/or agency practice(s) and what is being proposed in this regulatory action.

Current section	Current requirement	Proposed change, intent, rationale, and likely
number		impact of proposed requirements
310	Sets out the rules for partial dispensing of Schedule II prescriptions	Subsection E is added to allow a prescription for a prescription for a Schedule II drug to be filled in partial quantities if the partial fill is requested by the patient or by the practitioner who wrote the prescription provided the following are met: 1) The total quantity dispensed in all partial fillings does not exceed the total quantity prescribed; 2) The prescription is written and filled in accordance with state and federal law; and 3) The remaining portions are filled not later than 30 days after the date on which the prescription is written.  The changes are consistent with the Comprehensive Addiction and Recovery Act

(CARA) of 2016. The Board reviewed Section 309 of the Controlled Substances Act (21 U.S.C. 829) and concluded that the language proposed is in compliance with CARA. With a requirement that the total quantity dispensed cannot exceed the original prescription and that any remaining portions must be dispensed within 30 days, the partial fillings is contained to a pre-determined quantity within a set period of time. The intent is to give patients and prescribers the ability to obtain only the quantity of drugs necessary for a number of days, with the ability to complete the dispensing within 30 days if the full quantity is needed. A patient has the opportunity to try a new drug to determine its effectiveness or its potential for an adverse reaction without paying for the full quantity that may prove to be unnecessary or unwanted.

Form: TH-04